Biogenensis, functions, and clinical implications of circular RNAs in non-small cell lung cancer

Ying Liu,1,2 Xiang Ao,2 Wanpeng Yu,2 Yuan Zhang,1 and Jianxun Wang2

Lung cancer (LC) is the leading cause of cancer-related deaths worldwide, with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is a major pathological type of LC and accounts for more than 80% of all cases. Circular RNAs (circRNAs) are a large class of non-coding RNAs (ncRNAs) with covalently closed-loop structures, a high abundance, and tissue-specific expression patterns. They participate in various pathophysiological processes by regulating complex gene networks involved in proliferation, apoptosis, migration, and epithelial-to-mesenchymal transition (EMT), as well as metastasis. A growing number of studies have revealed that the dysregulation of circRNAs contributes to many aspects of cancer progression, such as its occurrence, metastasis, and recurrence, suggesting their great potential as efficient and specific biomarkers in the diagnosis, prognosis, and therapeutic targeting of NSCLC. In this review, we systematically elucidate the characteristics, biogenesis, and functions of circRNAs and focus on their molecular mechanisms in NSCLC progression. Moreover, we highlight their clinical implications in NSCLC treatment.

INTRODUCTION

Lung cancer (LC) is one of the most common malignant diseases of the respiratory system and the leading cause of cancer-related deaths worldwide.1 In recent years, the mortality of LC has decreased due to the introduction of screening guidelines and reductions in tobacco use. However, it is still a major public health problem, with poor 5-year overall survival (less than 20%).2,3 According to its pathological features, LC is usually classified into two subtypes: small cell LC and non-small cell LC (NSCLC). NSCLC is a major pathological type of LC and accounts for more than 80% of all cases, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).3 Clinically, it is difficult to observe the early symptoms of NSCLC due to its pathophysiological characteristics, leading to a large number of patients diagnosed at an advanced stage. In addition, incomplete treatment, as well as metastases or relapse in certain patients, contributes to the poor prognosis of patients with NSCLC.4 Therefore, the identification of efficient and specific biomarkers for diagnosis and prognosis, as well as the discovery of new therapeutic targets, is urgently needed to improve the diagnosis and treatment of NSCLC patients.

Circular RNAs (circRNAs) are a large class of non-coding RNAs (ncRNAs) and are characterized by the formation of covalently closed-loop structures without 5’ caps and 3’ poly(A) tails.5 Compared with linear RNAs, they are relatively more stable and not easily degraded by RNase.6 The first circRNA molecule was identified in RNA viruses via electron microscopy in the early 1970s.7 They were initially considered to be aberrant by-products of splicing without any important function in biological processes.8 However, with the rapid development of high-throughput sequencing technologies and bioinformatics, a large number of circRNAs have been identified in eukaryotes. Many of these circRNAs are shown to be involved in the regulation of many physiological processes of higher organisms.8

In recent years, a growing amount of evidence has shown that the dysregulation of circRNAs is involved in the occurrence and development of many cancer types, including NSCLC.9–12 circRNAs play crucial roles in the regulation of cancer progression by modulating the expression of key genes involved in proliferation, apoptosis, migration, and epithelial-to-mesenchymal transition (EMT), as well as metastasis.13 Moreover, the distinct covalently closed-loop structure of circRNAs grants them multiple characteristics, including stability, tissue specificity, and conservation in humans. These characteristics endow circRNAs with great potential as biomarkers for the early diagnosis and prognosis of cancer patients. They may even act as therapeutic targets for cancer. However, studies on NSCLC-related circRNAs are still lacking, and the detailed mechanisms of these molecules in NSCLC are also unclear.

In this review, we provide a detailed description of recent findings regarding the biogenesis, features, and functional roles of circRNAs and highlight their potential as biomarkers and therapeutic targets in the diagnosis and treatment of NSCLC.
OVERVIEW OF circRNAs

Biological characteristics of circRNAs
As a novel type of ncRNAs, a large number of circRNAs have been identified in different eukaryotic cells. circRNAs share several noteworthy biological features, including the following: (1) A diverse range of circRNAs have been widely detected in a series of species, including yeasts, plants, fungi, mouse, rat, monkey, fruit fly, human, and many other organisms. Moreover, circRNAs could be generated from a total of 5.8%–23% of actively transcribed human genes. It has been reported that approximately 20% of the genes in the human brain generate circRNAs, whereas in the heart, approximately 9% of the expressed genes produce circRNAs. (2) Due to their unique covalently closed-loop structure, circRNAs are more stable and have longer half-lives in tissues and plasma than linear RNAs, which are easily degraded by RNase R. This feature contributes to the accumulation of circRNAs in cells and their extensive biological functions. (3) circRNAs are generally expressed at a low level compared with their corresponding linear mRNAs. However, some studies have reported that the expression of a circRNA does not correlate with the expression of its cognate linear mRNA; in fact, under certain circumstances, circRNAs are expressed at a much higher level than their linear counterparts, even by several-fold. (4) The majority of circRNAs appear to be highly conserved regardless of the evolutionary distance between species, which may result from the conservation of back-splicing junctions in circRNAs. For instance, approximately 5%–10% of circRNAs are orthologous between the human brain and the porcine brain. (5) Different genomic origins of circRNAs exhibit diverse distributions in the compartments of eukaryotes. circRNAs generated from exons are mainly localized in the cytoplasm, while circRNAs generated from introns are localized in the nucleus. circRNAs are often expressed in cell-, tissue-, and developmental-stage-specific patterns in different species. For instance, circRNAs appear to have a higher expression level in low-proliferating cells, such as cardiomyocytes, compared with the high-proliferating cells of the liver. Increased levels of circRNAs have been observed in developing organs, such as heart, lung, and brain tissues. This feature indicates their crucial roles in the regulation of different biological processes.

Biogenesis of circRNAs
circRNAs are mainly produced from precursor mRNAs (pre-mRNAs) via a back-splicing process that ligates an upstream 3’ splice site with a downstream 5’ splice site to form a single-strand, covalently closed-loop structure. According to their genomic origin, circRNAs are generally divided into three classes: exonic circRNAs (ecirRNAs), intronic circRNAs (ciRNAs), and exon-intron circRNAs (EIciRNAs). Among them, ecirRNAs are the most abundant, accounting for nearly 85% of all identified circRNAs. ecirRNAs are mainly located in the cytoplasm after biogenesis, whereas the majority of ciRNAs and EIciRNAs are located in the nucleus.

Canonical splice signals and canonical spliceosomal machinery are reported to be necessary components of back-splicing circularization; however, the detailed mechanisms involved in spliceosome action in the back-splicing process are still not fully clarified. Currently, three hypothetical models of circRNA formation are proposed to explain the back-splicing process: lariat-driven circularization, intron-pair-driven circularization, and RNA-binding protein (RBP)-driven circularization (Figure 1). These models can be further summarized into two mechanisms according to the order in which the direct back-splicing or exon skipping occurs. In the model of lariat-driven circularization, exon skipping occurs first, and the
downstream splicing donor of an exon covalently binds to the upstream splice acceptor of another non-adjacent exon to form a lariat intermediate by exon skipping. Subsequently, the intron sequence in the lariat intermediate is removed through spliceosome-mediated splicing, thus forming ecirRNAs.27 In some certain cases, the intron between the exons may not be spliced out completely but preserved, leading to the formation of EIciRNAs.28 In models of intron-pair-driven circularization and RBP-driven circularization, back-splicing occurs first, and the two flanking introns generate a circular structure by direct base-pairing. This process is promoted by repeated Alu complementary elements or RBPs. Subsequently, all or part of the introns between the exons are excised to generate ecirRNA or EIciRNA.18,29 The biogenesis of ciRNAs occurs in a lariat-derived manner. Different from ecirRNAs and EIciRNAs, the formation of ciRNAs mainly depends on conserved motifs containing a 7-nt GU-rich element near the 5' splice site and an 11-nt C-rich element near the branchpoint site. In the process of back-splicing, the two elements combine to form a lariat structure, and then the exons and introns in the lariat structure are removed by the spliceosome, leading to the formation of stable ciRNAs.29

Collectively, the biogenesis of circRNAs and the regulation mechanisms involved in this process remain inconclusive. Further studies are required to understand these processes in depth.

Functions of circRNAs
With continuous in-depth studies on circRNAs, their biological functions have been gradually revealed in recent years (Figure 2). An increasing amount of evidence demonstrates that circRNAs are involved in the regulation of a series of pathophysiology processes.

**circRNAs act as miRNA sponges**
MicroRNAs (miRNAs) belong to the ncRNA family and are 20–25 nt in length.35 They are crucial regulators of gene expression, binding to specific miRNA-response elements (MREs) of target mRNAs to block
their translation or facilitate their degradation.\textsuperscript{36,37} It has been reported that a large number of circRNAs contain MREs and can act as intracellular competitive endogenous RNAs (ceRNAs) or miRNA sponges to weaken the effects of miRNAs on downstream target miRNAs, thereby regulating the expression of correlated genes.\textsuperscript{36,38}

CiRS-7, also known as CDR1as, was the first identified circRNA with a powerful miRNA sponge function. It contains more than 70 conserved miR-7 binding sites and functions as a super-sponge to inhibit the biological activity and functions of miR-7.\textsuperscript{39,40} In recent years, the existence and importance of CiRS-7 serving as a miR-7 inhibitor have been demonstrated in the regulation progression of several types of cancer, including esophageal squamous cell carcinoma, NSCLC, gastric cancer, pancreatic cancer, colorectal cancer, papillary thyroid cancer, hepatocellular carcinoma, laryngeal squamous cell carcinoma, and ovarian cancer.\textsuperscript{41–50} Moreover, CiRS-7 also harbors a number of complementary miR-671 binding sites. By binding to miR-671, CiRS-7 induces its own degradation to release miR-7.\textsuperscript{51} Mouse testicular-specific circRNA Sry is another typical case that can also serve as an RNA sponge. circRNA Sry contains 16 conserved miR-138 binding sites. It has been reported that the overexpression of circRNA Sry inhibits the activity of miR-138, leading to the upregulation of the miR-138 target gene miR-769.\textsuperscript{59} In addition, our previous study showed that circ-ZKSCAN1 (hsa_circ_0001727) significantly upregulated the expression of FAM83A by sponging miR-330-5p, leading to the suppression of the mitogen-activated protein kinase (MAPK) signaling pathway.\textsuperscript{52}

In recent years, an increasing number of circRNAs have been confirmed to act as miRNA sponges.\textsuperscript{53} Some circRNAs also include multiple types of MREs, indicating that they can simultaneously modulate the expression of multiple target genes by targeting different miRNAs.\textsuperscript{54} However, not all circRNAs possess this function because some certain circRNAs contain few or even no binding sites for a single miRNA.

**circRNAs interact with proteins**

Serving as protein sponges, decoys, or scaffolds is another crucial role of circRNAs. They can regulate the cellular functions of proteins by physically interacting with them, thereby being involved in pathological and physiological processes. For instance, Tsitsipatis et al. showed that the overexpression of circPCNX inhibits the proliferation of human cervical carcinoma HeLa cells. Mechanistically, circPCNX serves as a protein sponge to prevent the binding of AUF1 to p21 mRNA by physically interacting with AUF, thereby promoting p21 mRNA stability and upregulating p21 expression, a major inhibitor of cell proliferation.\textsuperscript{55} Zhu et al. revealed that circZKSCAN1 competitively interacts with FMRP to block the binding of FMRP to β-catenin-binding protein-cell cycle and apoptosis regulator 1 (CCAR1) mRNA, leading to the inhibition of the Wnt signaling pathway in hepatocellular carcinoma.\textsuperscript{56} Moreover, circ-Amot1 can serve as a decoy to enhance c-Myc stability and its retention in the nucleus by directly interacting with c-Myc, leading to increased cell proliferation and decreased apoptosis in breast cancer.\textsuperscript{57} In addition, some circRNAs have been shown to function as scaffolds to promote the contact between two or more proteins. For instance, circNDUF2B acts as a scaffold to interact with E3 ubiquitin-protein ligase (TRIM25) and insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs) to promote the ubiquitin-dependent degradation of IGF2BPs, resulting in the inhibition of IGF2BP-mediated proliferation and metastasis of NSCLC cells.\textsuperscript{58} The interactions between circRNAs and proteins expand the regulatory functions of circRNAs, but the mechanisms are still inconclusive and require further study.

**Translation of circRNAs into proteins**

In eukaryotes, the canonical translation initiation is a complex process in which the open preinitiation complex (PIC) first binds to mRNA and then scans along it to locate the start codon. During this process, the 5' terminal cap structure of the mRNA mediates the interaction of PIC with mRNA.\textsuperscript{59} Therefore, circRNAs were initially considered to be untranslatable due to a lack of a 5' cap. However, with the deepening of the study, some circRNAs have been reported to contain the initiation codon AUG and putative open reading frames (ORFs),\textsuperscript{51} indicating that they possess great potential to translate into proteins or functional peptides.

In 1995, Chen et al. first reported that eukaryotic ribosomes could initiate translation on engineered circRNAs inserting internal ribosome entry site (IRES) elements in an \textit{in vitro} study.\textsuperscript{52} However, it was not until 2017 that Legnini et al. provided the first proof that endogenous circRNAs can, in fact, encode proteins in humans. They identified a functional circRNA, circ-ZNF609, which contains an IRES and can bind to the ribosome, thus being translated into a protein in a splicing-dependent but cap-independent manner.\textsuperscript{51} In addition to IRESs, N6-methyladenosine (m6A) modification can also drive the translation of circRNAs in a cap-independent manner. Yang et al. showed that m6A modification initiates the translation of circRNAs by recruiting the m6A recognition protein YTHDF3 and the translation initiation factor eIF4G2. This process can be promoted by the methyltransferase METTL3/14 and suppressed by the demethylase fat mass and obesity-associated gene (FTO).\textsuperscript{62} These studies strongly support the coding potential of circRNAs. However, there are only a few endogenous circRNAs that have been confirmed to possess this ability, which may be due to the low translation initiation efficiency of cap-independent translation. In addition, the functions of circRNA-encoded proteins are still unclear. Collectively, further studies are needed to identify a series of uncharacterized proteins and elucidate the mechanisms in which they are involved.

**Regulation of circRNAs on gene expression**

circRNAs have been shown to regulate gene expression in multiple ways, such as transcription, post-transcription, and alternative splicing. Different from e circRNAs, the majority of ElciRNAs and ciRNAs are localized in the nucleus and tend to function at the transcriptional or post-transcriptional level. For instance, Li et al. showed that ElciRNA (e.g., circEIF3J or circPAIP2) combines with U1 small nuclear ribonucleoproteins (U1 snRNPs) via an RNA-RNA interaction to form an ElciRNA-U1 snRNP compound, which further interacts with the polymerase II (Pol II) complex to facilitate the transcription
of an ElcRNA parental gene. Similarly, ciRNAs such as ci-ankrd52 and ci-sirt7 can also facilitate the transcription of their parental genes by interacting with the RNA Pol II complex. Consistent with this, the silencing of ciRNAs derived from the introns of ANKRD52 and SIRT7 results in the downregulation of their parent genes. ciRNAs are also involved in the regulation of gene expression by influencing alternative splicing. It has been reported that back-splicing can compete with canonical splicing to regulate alternative splicing in the pre-mRNA splicing process. For instance, circMBL, generated from the second exon of MBL pre-mRNA, competes with the canonical splicing of MBL pre-mRNA, thus decreasing the formation of linear RNA. These studies suggest that the regulation of gene expression may be a common mechanism for circRNAs.

Online databases of circRNAs

To facilitate the development of circRNA investigation, many online databases have been established (Table 1). These databases provide predictions of biological roles or regulatory networks of circRNAs.
Table 2. Dysregulated circRNAs in NSCLC

| CircRNA     | Expression | Sponge target       | Types of NSCLC tissues and cell lines                                                                 | Function                                                                                                                                                                                                 | Reference    |
|-------------|------------|---------------------|------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| circPTPRA   | down       | miR-96-5p           | 114 NSCLC tissue samples with various clinicopathologic features; H23, H1755, and H522 NSCLC cell lines | downregulation of circPTPRA is associated with metastasis and inferior survival outcomes of NSCLC patients; upregulation of circPTPRA inhibits NSCLC cell EMT and metastasis by sponging miR-96-5p to upregulate RASSF8 expression | Wei et al.   |
| circRNA_101237 | up       | miR-490-3p          | 303 NSCLC tissue samples with various clinicopathological features; A549 and H1299 NSCLC cell lines      | upregulation of circRNA_101237 predicts poor survival in NSCLC; circRNA_101237 overexpression promotes cancer cell proliferation, migration, and invasion by sponging miR-490-3p to upregulate MAPK1 expression | Zhang et al.  |
| circPTK2    | down       | miR-429, miR-200b-3p, miR-429, miR-200b-3p | 73 NSCLC tissue samples; A549, H1299, H1650, SPC-A1, Calu3, H226, H520, and SK-MES-1 NSCLC cell lines | circPTK2 inhibits TGF-β-induced EMT and metastasis in NSCLC by sponging miR-429/miR-200b-3p and miR-429/miR-200b-3p to increase TIF1γ expression                                                                 | Wang et al.  |
| circFGFR1   | up         | miR-381-3p          | 210 NSCLC tissue samples with various clinicopathologic features; H358, H1299, A549, HCC827, H1650, H838, and H292 NSCLC cell lines | downregulation of circFGFR1 is associated with poor prognosis of NSCLC patients; overexpression of circFGFR1 promotes NSCLC cell migration, invasion, proliferation, and immune evasion by sponging miR-381-3p to upregulate CXCR4 expression | Zhang et al.  |
| circ_ZFR    | up         | miR-195-5p          | 64 NSCLC tissue samples; A549 and H460 NSCLC cell lines                                                                                                  | silencing circ_ZFR inhibits PTX resistance, cell-cycle process, proliferation, migration, and invasion and promotes apoptosis in PTX-resistant NSCLC cells by sponging miR-195-5p to upregulate KPNA4 expression | Li et al.     |
| circGFRA1   | up         | miR-188-3p          | 30 NSCLC tissue samples; A549 and H803 NSCLC cell lines                                                                                                  | upregulation of circGFRA1 promotes cancer cell proliferation by sponging miR-188-3p to activate the PI3K/AKT signaling pathway                                                                    | Yao et al.   |
| hsa_circ_0014130 | up       | miR-136-5p          | 30 NSCLC tissue samples; A549 and PC-9 NSCLC cell lines                                                                                                  | downregulation of hsa_circ_0014130 suppresses NSCLC progression by sponging miR-136-5p to increase Bcl-2 expression                                                                                       | Geng et al.  |
| hsa_circ_0062389 | up       | miR-103a-3p         | 33 NSCLC tissue samples with various clinicopathologic features; H1650, H23, H522, A549, H1703, and H460 NSCLC cell lines | high expression of hsa_circ_0062389 is associated with advanced TNM stage and lymph node metastasis in NSCLC patients; downregulation of hsa_circ_0062389 inhibits NSCLC cell proliferation and arrests cell cycle in G0/ G1 phase by sponging miR-103a-3p to upregulate CCNE1 expression | She et al.   |
| hsa_circ_0018818 | up       | miR-767-3p          | 30 NSCLC tissue samples with various clinicopathologic features; A549, PC-9, NCI-H441, and NCI-H1650 NSCLC cell lines | silencing hsa_circ_0018818 inhibits the proliferation and invasion of NSCLC cells and promotes apoptosis by sponging miR-767-3p to increase NID1expression; hsa_circ_0018818 knockdown also inhibits the EMT process and PI3K/Akt signaling pathway | Xu et al.    |

(Continued on next page)
| CircRNA     | Expression | Sponge target | Types of NSCLC tissues and cell lines                                                                 | Function                                                                                                                                                                                                 | Reference |
|------------|------------|---------------|------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| circ_100565 | Up         | miR-506-3p    | 50 NSCLC tissue samples; Calu-3, Calu-6, A549, and H1299 NSCLC cell lines                            | high expression of circ_100565 is associated with poor overall survival in NSCLC patients; downregulation of hsa_circ_0062389 inhibits the proliferation, migration, and invasion of NSCLC cells in vitro and reduces the tumor growth of NSCLC by sponging miR-506-3p to upregulate HMGA2 expression | Li et al.88 |
| circMET    | Up         | miR-145-5p    | 94 NSCLC tissue samples with various clinicopathologic features; A549, 95C, 95D, HBE, NCI-H1299, and NCI-H460 NSCLC cell lines | independent diagnostic and prognostic factor; overexpression of circMET promotes NSCLC cell proliferation, metastasis, and immune evasion by sponging miR-145-5p to upregulate CXCL3 expression | Pei et al.89 |
| circMAGI3  | Up         | miR-515-5p    | 30 NSCLC tissue samples with various clinicopathologic features; H322, H460, A549, and H1299 NSCLC cell lines | high expression of circMAGI3 is associated with poor prognosis in NSCLC patients; circMAGI3 promotes the glycolysis and proliferation of NSCLC cells by sponging miR-515-5p to upregulate HDGF expression | Guo et al.90 |
| circ_0072088| Up         | miR-377-5p    | 45 NSCLC tissue samples; A549 and H1299 NSCLC cell lines                                            | circ_0072088 inhibits proliferation and motility of NSCLC cells by sponging miR-377-5p to upregulate NOVA2 expression                                                                                     | Tan et al.91 |
| circ_0007385| Up         | miR-519d-3p   | 75 NSCLC tissue samples; A549, HCC827, H1975, and H2342 NSCLC cell lines                            | high expression of circ_0007385 is associated with poor prognosis in NSCLC patients; downregulation of circ_0007385 inhibits the proliferation, migration, invasion, and DDP resistance of NSCLC cells by sponging miR-519d-3p to upregulate HMGB1 expression | Ye et al.92 |
| circRNA CDR1as | Up     | miR-641      | A549, H1299, and Calu6 NSCLC cell lines                                                            | silencing of circRNA CDR1as suppresses the stemness of DDP-resistant NSCLC cells by sponging miR-641 to downregulate HOXA9 expression                                                                       | Zhao et al.93 |
| circTUBA1C  | Up         | miR-143-3p    | 30 NSCLC tissue samples; A549 and Calu-3 NSCLC cell lines                                         | knockdown of circTUBA1C inhibits cell proliferation and induces cell apoptosis in NSCLC by sponging miR-143-3p                                                                                            | Yang et al.94 |
| circHIPK3   | Up         | miR-107      | H1299, A549, and BEAS-2B NSCLC cell lines                                                          | circHIPK3 promotes the migration and proliferation of NSCLC cells by sponging miR-107 to upregulate BDNF expression                                                                                       | Hong et al.95 |
| circ_0074027| up         | miR-335-5p    | 60 NSCLC tissue samples; H358, H1299, H1581, and A549 NSCLC cell lines                            | circ_0074027 promotes cell viability, cell-cycle process, and colony formation and inhibits apoptosis in NSCLC cells by sponging miR-335-5p to increase GUL14B expression                                                   | Yu et al.96 |
| circSEC31A  | up         | miR-376a     | 44 NSCLC tissue samples; A549 and H1299 NSCLC cell lines                                          | circSEC31A promotes NSCLC cell migration, invasion, and glycolysis and inhibits apoptosis by sponging miR-376a to increase SEC31A expression                                                                            | Cheng et al.97 |
| hsa_circ_0046263 | up     | miR-940     | 45 NSCLC tissue samples; A549 and H1299 NSCLC cell lines                                         | hsa_circ_0046263 promotes NSCLC cell proliferation, cell cycle, and metastasis and induces apoptosis by sponging miR-940 to upregulate NOVA2 expression                                                      | Li et al.98 |

(Continued on next page)
in human diseases, including cancer, which is of great benefit to circRNA identification, localization, characterization, and functional analysis, as well as tools for analyzing the association of circRNAs with their targets. However, there are still some limits, such as a little overlap in predictions and a clear lack of standardized nomenclature. Therefore, these databases still require continual improvement. Also, the naming rules of circRNAs need to be unified.

**circRNAs and NSCLC**

circRNAs play crucial roles in the regulation of NSCLC development and progression by targeting cancer-related signaling pathways and/or regulating the expression of genes involved in the pathological progression of NSCLC, including cell proliferation, apoptosis, metastasis, and stemness, as well as resistance to therapy. In addition, some circRNAs have been shown to be differentially expressed between NSCLC tissues and corresponding normal tissues, indicating their great potential as promising biomarkers for the early diagnosis and prognosis of NSCLC. Here, we summarize some dysregulated circRNAs that have been found to be associated with NSCLC (Table 2).

**Expression profiles of circRNAs in NSCLC**

With the development of detection techniques and bioinformatics, an increasing number of circRNAs have been identified in NSCLC. Many of them have aberrant expression levels and are closely associated with NSCLC progression. Zhang et al. conducted a circRNA microarray analysis and distinguished 171 differentially expressed circRNAs, among which 148 were upregulated and 23 were downregulated in NSCLC tissues compared with normal tissues. In addition, some circRNAs have been shown to be differentially expressed between NSCLC tissues and corresponding normal tissues, indicating their great potential as promising biomarkers for the early diagnosis and prognosis of NSCLC. Here, we summarize some dysregulated circRNAs that have been found to be associated with NSCLC (Table 2).

**Table 2. Continued**

| CircRNA     | Expression | Sponge target | Types of NSCLC tissues and cell lines                                                                 | Function                                                                                                                                   | Reference |
|-------------|------------|---------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| circ-ABCB10 | up         | miR-584-5p    | 40 NSCLC tissue samples with various clinicopathologic features: SPC-A1, H1975, HCC427, H1650, PC9, and A549 NSCLC cell lines | high expression of circ-ABCB10 is associated with poor prognosis in NSCLC patients; upregulation of circ-ABCB10 promotes the migration, cell proliferation, and invasion of NSCLC cells by sponging miR-584-5p to upregulate EIF5 expression | Ma et al.99 |
| hsa_circ_0102231 | up        | miR-145      | A549, NCI-H358, NCI-H1650, HCC827, and NCI-H1299 NSCLC cell lines                                  | hsa_circ_0102231 facilitates the proliferation and invasion of NSCLC cells by sponging miR-145 to increase RBBP4 expression | Cao et al.100 |
| circ-FOXM1  | up         | miR-149-5p    | 72 NSCLC tissue samples; A549 and H1581 NSCLC cell lines                                         | circ-FOXM1 promotes NSCLC cell viability, migration, and autophagy and inhibits cell apoptosis by sponging miR-149-5p to increase ATG5 expression | Wei et al.101 |
| circ_0020123 | up         | miR-384      | 33 NSCLC tissue samples; A549 and H1581 NSCLC cell lines                                         | circ_0020123 promotes the viability, migration, invasion, and EMT and inhibits apoptosis of NSCLC cells by sponging miR-384 to upregulate TRIM44 expression | Ma et al.102 |
| circNDUF2   | down       | –             | 55 NSCLC tissue samples with various clinicopathologic features: A549, H1299, HCC827, H1975, H1703, H460, and H1650 NSCLC cell lines | overexpression of circNDUF2 suppresses the growth and metastasis of NSCLC cells by acting as a scaffold to enhance the interaction between TRIM25 and IGF2BP3s | Li et al.58 |
| circSATB2   | up         | miR-326      | 59 NSCLC tissue samples; A549, H460, H1299, H226, and MES-1 NSCLC cell lines                   | circSATB2 facilitates the proliferation, migration, and invasion of NSCLC cells, as well as inducing abnormal proliferation of normal human bronchial epithelial cells by sponging miR-326 to increase actin-bundling protein 1 expression | Zhang et al.11 |
| circ-CPA4   | up         | let-7 miRNA   | 50 NSCLC tissue samples with various clinicopathologic features: A549, H1299, SK-MES-1, and Calu-3 NSCLC cell lines | circ-CPA4 promotes cell growth, mobility, EMT, and cell death in NSCLC cells by sponging let-7 miRNA to upregulate PD-L1 expression | Hong et al.103 |

**Table Notes:**
- circRNA, circular RNA; NSCLC, non-small cell lung cancer; EMT, epithelial-to-mesenchymal transition; DDP, cisplatin; Ras, Ras association domain family 8; MAPK1, mitogen-activated protein kinase 1; TIF1y, transcriptional intermediary factor 1γ; CXCR4, chemokine receptor 4; PTX, pentraxin; RASSF8, Ras association domain family 8; CCNE1, cyclin E1; PI3K, phosphatidylinositol 3-kinase; HMGA2, high-mobility group AT-hook 2; CXCL3, chemokine (C-X-C motif) ligand 3; HDGF, hepatoma-derived growth factor; NOV2A, NOVA alternative splicing regulator 2; HMGB1, high-mobility group box 1; HOXA9, homeobox protein Hox-A9; BDNF, brain-derived neurotrophic factor; GUL4B, cullin 4B; SEC31A, SEC31 homolog A; RBBP4, retinoblastoma-binding protein 4; ATG5, autophagy-related 5; TRIM44, tripartite motif-containing protein 44; IGF2BP3s, insulin-like growth factor 2 mRNA-binding proteins; PD-L1, programmed cell death ligand 1.
| Signaling pathway | circRNA     | Expression | Key message(s)                                                                                                                                                                                                 | Reference |
|-------------------|-------------|------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
|                   | hsa_circ_000984 | up         | high hsa_circ_000984 expression predicts poor prognosis in NSCLC patients, indicating its potential as a diagnostic biomarker for NSCLC; knockdown of hsa_circ_000984 results in the inhibition of the Wnt/β-catenin signaling pathway by downregulating β-catenin, cyclin D1, and c-Myc expression in NSCLC cells | Li et al.109 |
| Wnt/β-catenin     | circ_0067934 | up         | silencing of circ_0067934 inactivates the Wnt/β-catenin signaling pathway by decreasing the expression of β-catenin, cyclin D1, and c-Myc in NSCLC cells; overexpression of circ_0067934 has the opposite effect on the Wnt/β-catenin signaling pathway | Zhao et al.110 |
|                   | circ-ZNF124  | up         | knockdown of circ-ZNF124 downregulates the expression of β-catenin and c-Myc by targeting the miR-498/YES axis, leading to the inactivation of the Wnt/β-catenin signaling pathway; these findings suggest the potential of circ-ZNF124 as a therapeutic target for NSCLC | Gao et al.111 |
|                   | circ_001569  | up         | high expression of circ_001569 predicts poor prognosis in NSCLC patients, suggesting its potential as a diagnostic biomarker for NSCLC; silencing of circ_001569 inhibits the Wnt/β-catenin pathway by reducing the expression of WNT1, β-catenin, and TCF4 in NSCLC cells | Ding et al.112 |
|                   | hsa_circ_0043256 | up     | hsa_circ_0043256 inhibits the Wnt/β-catenin pathway by sponging miR-1252 to upregulate the expression of ITCH (Wnt/β-catenin pathway inhibitor protein), indicating that hsa_circ_0043256 might be a potential therapeutic target for NSCLC | Tian et al.113 |
| PI3K/AKT          | circPRKCA   | up         | high expression of circPRKCA is associated with TNM stage and lymph node metastasis in NSCLC patients; knockdown of circPRKCA upregulates the expression of PDK1 by sponging miR-330-5p, leading to the inactivation of the PI3K/AKT signaling pathway | Bai et al.114 |
|                   | circGFRA1   | up         | overexpression of circGFRA1 significantly upregulates the expression of p-AKT in NSCLC cells, whereas LY294002 treatment blocks the increased expression of p-AKT caused by circGFRA1 overexpression | Yao et al.115 |
|                   | circRNA_100876 | up         | silencing of circRNA_100876 inhibits the proliferation, migration, and invasion of NSCLC cells by sponging mir-636, leading to inhibition of the PI3K/Akt signaling pathway | Song et al.116 |
|                   | hsa_circ_0018818 | up     | hsa_circ_0018818 promotes the proliferation and invasion of NSCLC cells and induces their apoptosis by targeting miR-767-3p to upregulate NID1 expression, leading to activation of the PI3K/Akt signaling pathway | Xu et al.117 |
|                   | circFGFR3   | up         | circFGFR3 promotes the invasion and proliferation of NSCLC cells by sponging miR-22-3p to upregulate the expression of Gal-1, p-AKT, and p-ERK1/2 | Qiu et al.118 |
|                   | circ-ACACA  | up         | circ-ACACA promotes the proliferation and migration of NSCLC cells and decreases the glycolysis rate by targeting miR-1183 to activate the PI3K/Akt signaling pathway | Wu et al.119 |

(Continued on next page)
356 differentially expressed circRNAs between four paired NSCLC tissues and adjacent normal tissues, including 204 upregulated circRNAs and 152 downregulated circRNAs. Most of them were ecirRNAs.105 In another study, by comparing NSCLC tumors with adjacent normal tissues, Wang et al. confirmed 50 differentially expressed circRNAs in LUAD tissues, 172 differentially expressed circRNAs in LUSC tissues, and 26 differentially expressed circRNAs in both LUAD and LUSC tissues.106 Furthermore, Liu et al. identified 1,377 differentially expressed circRNAs via a microarray screening analysis, among which 989 were upregulated and 98 were downregulated in the plasma samples of geftinib-effective NSCLC patients compared with geftinib-ineffective NSCLC patients.107 Li et al. reported 121 differentially expressed circRNAs using public NSCLC datasets obtained from the Gene Expression Omnibus (GEO) database, among which 43 were upregulated and 78 were downregulated in NSCLC tissues.108

**circRNAs target signaling pathways in NSCLC**

An increasing number of studies have shown that circRNAs are involved in NSCLC progression by targeting cancer-related signaling pathways, such as the Wnt/β-catenin, PI3K/AKT, and MAPK signaling pathways (Table 3). This may provide us with new insights into NSCLC progression in order to understand the exact effect and molecular mechanism of circRNAs in signaling pathway regulation. The Wnt/β-catenin signaling pathway is closely correlated with fundamental cellular functions, such as cell proliferation, apoptosis, and metastasis. The aberrant activation of the Wnt/β-catenin signaling pathway has been widely observed in a series of cancers, including NSCLC.122,123 Some circRNAs have been reported to contribute to NSCLC progression by modulating the expression of key components in the Wnt/β-catenin signaling pathway. For instance, Li et al. found that the knockdown of circRNA hsa_circ_000984 in human NSCLC cell lines A549 and H1299 significantly decreases the expression of β-catenin, cyclin D1, and c-Myc at both the mRNA and the protein level, indicating that hsa_circ_000984 affects NSCLC progression by enhancing the Wnt/β-catenin signaling pathway.109 Another study showed that silencing circ_001569 significantly downregulates the expression of Wnt1, β-catenin, and transcription factor 4 in NSCLC cells.112

| Table 3. Continued |
|-------------------|
| Signaling pathway | circRNA | Expression | Key message(s)                                                                 |
| MAPK              | hsa_circ_0004050 | down     | high expression of hsa_circ_0004050 predicts good prognosis in NSCLC patients; hsa_circ_0004050 promotes apoptosis and inhibits proliferation of NSCLC cells by targeting miR-1233-3p to upregulate the expression of DUSP9, leading to the inhibition of the ERK/JNK signaling pathway |
| NER               | hsa_circ_0001946 | up      | silencing of hsa_circ_0001946 promotes the viability, proliferation, migration, and invasion of NSCLC cells and induces apoptosis by upregulating the expression of XPA, XPC, Rad23B, RPA14, RPA32, RPA70, and ERCC1, leading to the activation of the NER signaling pathway |
| E2F2              | circPVT1     | up      | circPVT1 promotes NSCLC cell proliferation, migration, and invasion and induces apoptosis by sponging miR-125b to upregulate the expression of E2F2 |

**Additional information:**
circRNA, circular RNA; NSCLC, non-small cell lung cancer; PI3K, phosphatidylinositol 3-kinase; PDK1, phosphoinositide-dependent kinase 1; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated kinase; NER, nucleotide excision repair; XPC, xeroderma pigmentosum group C; RPA, replication protein A; ERCC1, excision repair cross-complementing 1; E2F, E2F transcription factor 2; PVT1, plasmacytoma variant translocation 1; NID1, nidogen 1; Gal-1, galectin-1.
Some other circRNAs have been shown to indirectly regulate the Wnt/β-catenin pathway by sponging miRNAs. For instance, hsa_circ_0043256 promotes the expression of Itchy E3 ubiquitin protein ligase (a negative regulator of the Wnt/β-catenin signaling pathway) by sponging miR-1252, leading to the inactivation of the Wnt/β-catenin signaling pathway. Similarly, circ-ZNF124 upregulates the expression of YES proto-oncogene 1 (YES1) by sponging miR-498, resulting in the inactivation of the Wnt/β-catenin signaling pathway.

The PI3K/AKT signaling pathway plays crucial roles in regulating various biological processes of cells, such as cell cycle, glucose transport, and carcinogenesis. Several circRNAs have been shown to regulate the carcinogenesis of NSCLC by targeting the PI3K/AKT signaling pathway. For instance, Yao et al. found that circGFRA1 activates the PI3K/AKT signaling pathway by sponging miR-188-3p, leading to the promotion of the proliferation of NSCLC cell lines A549 and NCI-H838. Consistent with this, LY264002 (a classical PI3K inhibitor) can reverse the positive effect of circGFRA1 on the proliferation of NSCLC cells. Bai et al. revealed that circPRKCA enhances the activity of AKT by binding to miR-330-5p in NSCLC cells. Moreover, Xu et al. showed that the knockdown of circRNA_100876 significantly downregulates the expression of p-AKT, resulting in the inhibition of NSCLC progression. The negative effect of circRNA_100876 knockdown on the expression of p-AKT is reversed by miR-636 downregulation. In addition, circFGFR3 and hsa_circ_0018818 have also been demonstrated to promote the proliferation of NSCLC by activating the PI3K/AKT signaling pathway.

The MAPK signaling pathway is a classical carcinogenic pathway. The dysregulation of the MAPK/ERK cascade contributes to many aspects of cancer progression. Wang et al. found that circ-ZKSCAN1 suppresses the growth of NSCLC cells. Mechanistically, circ-ZKSCAN1 upregulates the expression of FAM83A by sponging miR-330-5p, leading to the inhibition of the MAPK signaling pathway. Moreover, hsa_circ_004050 is reported to downregulate the expression of DUSP9 by sponging miR-1233-3p in the NSCLC cell line A549 and then inhibiting the ERK/JNK signaling pathway. In our previous work, circ-ZKSCAN1 was found to be upregulated in both NSCLC tissues and cell lines. The overexpression of circ-ZKSCAN1 inhibits the MAPK signaling pathway by sponging miR-330-5p to increase FAM83A expression, leading to an enhancement in NSCLC cell growth. circRNAs can also modulate NSCLC progression by targeting the nucleotide excision repair (NER) signaling pathway. For instance, the silencing of circ-ZKSCAN1 inhibits NSCLC cells to the chemotherapeutic drug cisplatin (DDP) and increases the DNA repair ability by activating the NER signaling pathway. Collectively, these studies indicate that circRNAs are key factors in the regulation of NSCLC signaling pathways (Figure 3). Understanding the mechanisms of circRNAs in the regulation of NSCLC signaling pathways may provide new therapeutic strategies for NSCLC patients.

Roles of circRNAs in NSCLC progression

Continuous proliferation and evasion from apoptosis are characteristic changes in cancer cells. However, the detailed mechanisms of these cellular processes are very complex and not fully elucidated. A large number of oncogenic circRNAs (e.g., circ-ABCB10, circRNA_103993, and circ_004130) have been demonstrated to facilitate proliferation and suppress apoptosis in NSCLC cells. Consistent with this, the upregulation of these circRNAs has been observed in NSCLC tissues and cell lines. In contrast, some circRNAs (e.g., hsa_circ_0043256 and circ-LARP4) act as tumor suppressors to inhibit proliferation and facilitate apoptosis in NSCLC cells. Their expression is downregulated in NSCLC tissues and cells. Moreover, Chen et al. showed that knockdown of circRNA 100146 inhibits the proliferation of NSCLC cells and promotes apoptosis. Mechanistically, circRNA 100146 regulates the expression of related genes involved in these processes by interacting with multiple members of the splicing factor family SF3 and sponging miR-361-3p and miR-615-5p. Wang et al. found that the overexpression of hsa_circ_0004050 promotes the apoptosis and inhibits the proliferation of NSCLC cells by inhibiting the ERK/JNK signaling pathway.

Invasion and metastasis are the main causes of cancer recurrence and are closely associated with the mortality of NSCLC patients, and circRNAs have been shown to be important regulators of invasion and metastasis in NSCLC. For instance, Li et al. showed that circGFGR1 is highly expressed in NSCLC tissues. The overexpression of circGFGR1 facilitates the migration and invasion of NSCLC cells by sponging miR-381-3p to promote the expression of C-X-C motif chemokine receptor 4 (CXCR4). Chi et al. found that circPIP5K1A knockdown inhibits tumor growth and the pulmonary metastasis of NSCLC in mouse xenograft models. Mechanistically, circPIP5K1A facilitates the expression of HIF-1α by sponging miR-600, leading to the promotion of NSCLC proliferation and metastasis. Moreover, EML4-ALK and SLC34A2-ROSI are oncogenic fusion genes that contribute to NSCLC carcinogenesis and progression. Peng et al. revealed that F-circEA-2a derived from EML4-ALK variant 3b promotes the migration and invasion of NSCLC cells, whereas it has little effect on cell proliferation. They also identified two novel circRNAs (F-circSR1 and F-circSR2) generated from the SLC34A2-ROSI fusion gene and found that the two F-circSRs facilitate cell migration in NSCLC cells. EMT is a crucial physiological process that endows cells with migratory and invasive features. The dysregulation of EMT has been shown to be closely correlated with invasion and metastasis during cancer progression. An increasing number of studies have demonstrated that circRNAs can regulate the invasion and metastasis of NSCLC cells through the EMT process. For instance, the overexpression of circPTPRA in NSCLC cells increases the expression of E-cadherin (epithelial marker) and inhibits the expression of N-cadherin and vimentin (mesenchymal marker), whereas circPTPRA knockdown induces opposite molecular alterations, indicating the negative effect of circPTPRA on EMT. Further study demonstrated that circPTPRA inhibits the EMT process of NSCLC cells by sponging miR-96-5p to upregulate RASSF8 expression, leading to the suppression of invasion and metastasis in NSCLC.
Another study showed that circAGFG1 upregulates the expression of ZNF281 by sponging miR-203, leading to the promotion of EMT progress and the metastasis of NSCLC cells.139 In addition, the oncogenic or anti-tumoral features of circRNAs are at least partly due to their cell-cycle modulation. Cyclin D1 is a key cell-cycle regulator that mediates the entrance of a cell into the proliferative stage.140 Cui et al. showed that circ-CMPK1 upregulates the expression of cyclin D1 by sponging miR-302, thereby promoting the proliferation of NSCLC cells.141 Lu et al. revealed that the knockdown of hsa_circ_0096157 in DDP-resistant NSCLC cells decreases the expression of CDK4, cyclin D1, and Bcl-2 by upregulating the P21 protein, resulting in the inhibition of cell-cycle progression. Consistent with this, the overexpression of hsa_circ_0096157 causes opposite cellular and molecular alterations in NSCLC cells.142 Some other circRNAs, such as circ_0078767, circ_0072083, and circ-DENND2A, have also been reported to affect NSCLC progression by modulating the cell-cycle progress.143–145 These studies suggest that circRNAs exert their oncogenic or anti-tumoral roles in NSCLC progression through diverse mechanisms.

**circRNAs modulate the stemness of NSCLC cells**

Cancer stem cells (CSCs) are a unique subset of self-renewable tumor cells that are characterized by their "stem-like" characteristics, such as differentiation, metastasis, and tumor initiation. An increasing amount of evidence shows that they are the main cause of chemotherapeutic drug resistance, metastasis, and cancer recurrence.146,147 Therefore, the investigation of CSCs’ regulation mechanism may provide new insights into the development of NSCLC therapeutic strategies. Recent studies have revealed that circRNAs are crucial factors in the modulation of NSCLC CSC stemness. For instance, Hong et al. found that circ-CPA4 enhances the stemness of NSCLC cell lines A549 and H1299. Further study revealed that circ-CPA4 upregulates the expression of stemness markers (OCT4, SOX2, Nanog, and ALDH1) by sponging let-7 miRNA to increase programmed cell death ligand 1 (PD-L1) expression.103 Another study demonstrated that the silencing of circ_POLA2 reduces sphere-formation ability, ALDH1 activity, and stemness marker (Oct4 and Nanog) expression, indicating the positive role of circ_POLA2 in the promotion of NSCLC cell stemness. Mechanistically, circ_POLA2 upregulates the expression of G protein subunit β1 (GNB1) by sponging miR-326. Consistent with this, the overexpression of GNB1 reverses the inhibitory effect of circ_POLA2 knockdown on NSCLC cell stemness.148

**circRNAs and autophagy in NSCLC**

Autophagy is a conserved self-degradative process that plays a key role in regulating the degradation and recycling of organelles.159 It...
is recognized as a double-edged sword during cancer progression. On one hand, autophagy exerts its anti-tumoral function by eliminating oncogenic protein substrates, toxic unfolded proteins, and damaged organelles. On the other hand, it can promote cancer progression by mediating intracellular recycling, which provides substrates for metabolism and maintains the functions of the mitochondria. Therefore, understanding the mechanism of autophagy regulation may provide us with new insights into autophagy-based therapeutic interventions for NSCLC. An increasing amount of evidence has shown that circRNAs are involved in the regulation of autophagy in NSCLC cells. For instance, Wei et al. demonstrated that the silencing of circ-FOX1M1 inhibits the autophagy of NSCLC cells by sponging miR-851 to upregulate the expression of ATG7, thereby promoting cell chemoresistance. Collectively, circRNAs serve as oncogene or tumor suppressors to regulate NSCLC biological behaviors, including cell proliferation, invasion, apoptosis, metastasis, EMT, cell cycle, stemness, and chemotherapy sensitivity.

Regulation effect of circRNAs on chemotherapy sensitivity in NSCLC

Chemotherapy is one of the main treatment modalities for cancer; however, with the development of chemotherapy resistance and multidrug resistance (MDR), the therapeutic effect of chemotherapy will gradually decline over time until its failure. Therefore, in-depth research on the regulation mechanisms underlying NSCLC resistance may provide a novel theoretical basis for the improvement of NSCLC chemotherapy. Recent studies have shown that the dysregulation of circRNAs is involved in the regulation of NSCLC chemoresistance. For instance, Xu et al. identified 11,281 differentially expressed circRNAs via a circRNA microarray in the taxol-resistant NSCLC cell line A549 compared with parental A549 cells, among which 2,909 were upregulated and 8,372 were downregulated. Further study revealed that the dysregulated circRNAs block the sensitivity of NSCLC to taxol by negatively regulating the expression of miRNA transcripts. Li et al. showed that the overexpression of circ_0002483 enhances the sensitivity of NSCLC cells to taxol by sponging miR-182-5p to upregulate the expression of GRB2, FOXO1, and FOXO3. In addition, circ_ZFR has been found to be upregulated in NSCLC tissues and cell lines. The knockdown of circ_ZFR inhibits the taxol resistance of NSCLC by sponging miR-195-5p to decrease KPNA4 expression. Some circRNAs, such as circ_0007385 and circ-PRMT5, are reported to be involved in the regulation of the DDP resistance of NSCLC cells. circ_0007385 knockdown has been shown to repress the DDP resistance of NSCLC cells. Mechanistically, silencing circ_0007385 upregulates the expression of HMGB1 by sponging miR-519d-3p, leading to the inhibition of DDP resistance in NSCLC. circ-PRMT5 promotes DDP resistance in NSCLC cells by sponging miR-4458 to upregulate the expression of REV3-like DNA-directed polymerase ζ catalytic subunit (REV3L). Moreover, Xiao et al. showed that circRNA_103762 is highly expressed in NSCLC tissues and cell lines. The knockdown of circRNA_103762 suppresses the MDR of NSCLC cells by upregulating the expression of DNA damage-inducible transcript 3. In addition, hsa_circ_0004015 has been found to enhance the resistance of NSCLC cells to gefitinib by sponging miR-1183 to upregulate PDK1 expression. circFGFR1 has been shown to upregulate the expression of CXCR4 by sponging miR-381-3p, resulting in the resistance of NSCLC cells to anti-programmed cell death 1 (PD-1). Taken together, these studies suggest that circRNAs play crucial roles in the regulation of chemotherapy resistance and MDR, indicating their great potential as therapeutic targets or drugs for improving chemotherapy resistance and MDR in NSCLC.

CLINICAL APPLICATIONS of circRNAs IN NSCLC

circRNAs as diagnostic and prognostic biomarkers

Currently, it is difficult to observe the early symptoms of NSCLC due to its complex pathological characteristics, which results in most...
Table 4. circRNAs as diagnostic and prognostic biomarkers in NSCLC

| circRNA          | Expression | Function                | Clinical relevance                                                                 | Reference |
|------------------|------------|-------------------------|-------------------------------------------------------------------------------------|-----------|
| hsa_circ_0077837 | Down       | diagnostic biomarker    | hsa_circ_0077837 shows the diagenetic value for NSCLC patients; AUC = 0.921, 95% CI 0.868–0.975 | Wang et al.106 |
| hsa_circ_0001821 | Up         | diagnostic biomarker    | hsa_circ_0001821 shows the diagenetic value for NSCLC patients; AUC = 0.863, 95% CI 0.797–0.929 |           |
| circFARSA        | Up         | diagnostic biomarker    | plasma circFARSA shows the diagenetic value for NSCLC patients; AUC = 0.71, gender, p = 0.048 | Hang et al.167 |
| circSATB2        | up         | diagnostic biomarker    | circSATB2 is highly expressed in serumal exosomes with high sensitivity and specificity for clinical detection in NSCLC patients; AUC = 0.797 in serum from metastatic NSCLC patients | Zhang et al.171 |
| circRNA_100876   | up         | prognostic biomarker    | high expression of circRNA_100876 predicts poor prognosis for NSCLC patients (OS, p < 0.001); lymph node metastasis, p = 0.001, and tumor staging, p = 0.001 | Yao et al.168 |
| ciRS-7           | up         | prognostic biomarker    | high expression of ciRS-7 appears to be a powerful prognostic biomarker for NSCLC patients; HR 2.50, 95% CI 1.07–6.07, p < 0.001 | Tian et al.169 |
| circ_100565      | up         | prognostic biomarker    | high expression of circ_100565 predicts poor prognosis for NSCLC patients; lymph node metastasis, p = 0.011, and TNM stages, p = 0.002 | Li et al.88 |
| circ_000376      | up         | diagnostic biomarker    | circ_000376 expression is associated with unfavorable pathological parameters of NSCLC patients; T stage, p = 0.044, and lymph invasion, p = 0.0371 | Sun et al.170 |
| hsa_circ_0109320 | up         | prognostic biomarker    | upregulation of hsa_circ_0109320 predicts good prognosis in gefitinib-treated NSCLC patients; AUC = 0.81 for estimating the therapeutic effect of gefitinib | Liu et al.167 |
| circMET          | up         | diagnostic and prognostic biomarker | a high level of circMET is associated with short OS and PFS in NSCLC patients; differentiation, p = 0.015; tumor size, p = 0.006; lymph node metastasis, p = 0.008; OS, p < 0.001; and PFS, p < 0.001 | Pei et al.89 |
| circ_0001649     | down       | prognostic biomarker    | downregulation of circ_0001649 is associated with TNM stage (p = 0.010), lymph node metastasis (p = 0.029), and OS (p < 0.031) | Liu et al.171 |
| hsa_circ_0033155 | down       | diagnostic biomarker    | downregulation of hsa_circ_0033155 is associated with lymphatic metastasis (p = 0.0237) | Gu et al.172 |
| hsa_circRNA_012515 | up         | diagnostic and prognostic biomarker | high expression of hsa_circRNA_012515 is associated with tumor stage (p = 0.013), lymphatic metastasis (p = 0.039), OS (p = 0.003), and PFS (p = 0.018); AUC = 0.88 | Fu et al.173 |
| hsa_circ_000984  | up         | prognostic biomarker    | high expression of hsa_circ_000984 predicts poor prognosis for NSCLC patients; TNM stage, p = 0.004; lymph node metastasis, p = 0.005; OS, p = 0.0031; and PFS, p = 0.008 | Li et al.169 |
| circ-RAD23B      | up         | prognostic biomarker    | high expression of circ-RAD23B predicts poor prognosis for NSCLC patients; lymph node metastasis, p = 0.019; differentiation grade, p = 0.010; and OS (p = 0.033) | Han et al.174 |

(Continued on next page)
| circRNA               | Expression | Function                        | Clinical relevance                                                                                   | Reference       |
|----------------------|------------|---------------------------------|-----------------------------------------------------------------------------------------------------|-----------------|
| circ_0000079         | down       | prognostic biomarker            | low expression of circ_0000079 predicts poor prognosis for NSCLC patients; depth of invasion, p = 0.041; differentiation, p = 0.005; and OS, p = 0.0018 | Chen et al.175  |
| hsa_circ_0109320     | down       | prognostic biomarker            | high expression of hsa_circ_0109320 is associated with longer PFS in gefitinib-treated NSCLC patients; AUC = 0.8054, PFS, p = 0.02545 | Liu et al.107    |
| circ_0047921, circ_0056285, circ_0007761 | up         | diagnostic biomarkers           | circ_0047921, circ_0056285, and circ_0007761 show significant diagnostic validity for NSCLC; AUC = 0.926, 95% CI 0.895–0.956 | Xian et al.176   |
| hsa_circ_0075930     | up         | prognostic biomarker            | upregulation of hsa_circ_0075930 is associated with tumor size (p = 0.001) and lymph node metastasis (p = 0.038) | Li et al.177     |
| hsa_circ_0043265     | down       | diagnostic biomarker            | low expression of circ_0000079 is associated with tumor size (p = 0.0186), TNM stage (p = 0.0283), and lymph node metastasis (p = 0.0089) | Ren et al.133    |
| hsa_circ_0014130     | up         | diagnostic biomarker            | the expression of hsa_circ_0014130 is associated with TNM stage (p = 0.001) and lymphatic metastasis (p = 0.004); AUC = 0.878, 95% CI 0.804–0.951; p < 0.001 | Zhang et al.156  |
| circ_000376          | up         | prognostic biomarker            | high expression of circ_000376 is associated with TNM stage (p = 0.0007), tumor size (p < 0.0001), and lymph node metastasis (p = 0.0016) and predicts poor prognosis in NSCLC patients (OS, p = 0.008) | Li et al.178     |
| circ_0067934         | up         | prognostic biomarker            | high expression of circ_0067934 is associated with TNM stage (p = 0.003), lymph node status (p = 0.000), and distant metastasis (p = 0.017) and predicts poor prognosis in NSCLC patients (OS, p = 0.001) | Wang et al.176   |
| hsa_circ_0037515, hsa_circ_0037516 | down       | diagnostic biomarkers           | hsa_circ_0037515 and hsa_circ_0037516 show diagnostic value in NSCLC patients; for hsa_circ_0037515, AUC = 0.81, sensitivity 0.57, and specificity 0.9; for hsa_circ_0037516, AUC = 0.82, sensitivity 0.65, and specificity 0.84; for the combination of hsa_circ_0037515 and hsa_circ_0037516, AUC = 0.9, sensitivity 0.87, and specificity 0.89 | Zhao et al.140   |
| hsa_circ_0102533     | up         | diagnostic biomarker            | hsa_circ_0102533 shows diagnostic value for NSCLC patients; AUC = 0.744, 95% CI 0.622–0.867 (p = 0.001); high expression of hsa_circ_0102533 is associated with tumor type (p = 0.011), TNM stage (p = 0.010), lymph node metastasis (p = 0.001), and distant metastasis or recurrence (p = 0.021) | Zhou et al.181   |
| circPVT1             | up         | prognostic biomarker            | high expression of circPVT1 is associated with TNM stage (p = 0.007) and tumor size (p = 0.022) and predicts poor prognostic in NSCLC patients | Qin et al.162    |
| circsSMARCA5         | down       | prognostic biomarker            | low expression of circsSMARCA5 is associated with TNM stage (p = 0.012) and tumor size (p = 0.004) and predicts poor prognostic in NSCLC patients (OS, p = 0.022) | Zhang et al.155  |
| novel_circ_0005280   | down       | diagnostic and prognostic biomarker | low expression of novel_circ_0005280 predicts poor prognosis in NSCLC patients; AUC = 0.944, cutoff 10.23; sensitivity 85.2%; specificity 95.1%; tumor diameter, p = 0.001; and age, p = 0.021 | Li et al.184     |

(Continued on next page)
patients being diagnosed at an advanced stage, as well as the loss of the best opportunity for surgical treatment.\(^\text{160}\) In addition, a poor prognosis assessment seriously affects the adjustment of treatment strategies for individual patients and the prolongation of their lifespan. In recent years, multiple conventional biomarkers, such as AFP, PD-L1, and ALK, have been applied to the diagnosis and prognosis evaluation of cancers, including NSCLC.\(^\text{160–164}\) However, the low specificity and sensitivity of these protein biomarkers restrict their further utilization. For instance, AFP is the most efficient biomarker for hepatocellular carcinoma (HCC) diagnosis, but a study has shown that in up to 40% of patients with HCC, AFP expression is at a normal level, which illustrates the low sensitivity.\(^\text{165}\) miRNAs are also a class of biomarker candidates with great potential. However, the relatively short half-life and low stability of miRNAs limit their translation from basic research to clinical application. With the development of circRNA investigation, these limitations are being gradually overcome. For instance, Yu et al. identified a plasma circRNA panel (CircPanel) containing three circRNAs (hsa_circ_0000976, hsa_circ_0007750, and hsa_circ_0139897) from HCC patients and demonstrated that the CircPanel has a higher accuracy than AFP at distinguishing HCC patients from controls.\(^\text{166}\) An increasing amount of evidence suggests that circRNAs are ideal biomarkers for the diagnosis and prognosis of cancers, including NSCLC, due to their high stability, specificity, and detectability.\(^\text{3,4}\) Currently, quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) is the favored method to detect circRNA and miRNA in clinical samples. Sequence-specific probes and primers are required in this system. Compared with circRNA, it is more difficult to design effective specific primers and probes for miRNAs due to their short length, which makes circRNA a more ideal biomarker. circRNAs that might serve as diagnostic and prognostic biomarkers in NSCLC are listed in Table 4.

Pei’s study revealed that circMET is upregulated in NSCLC tissues compared with the normal control, and its upregulation in NSCLC is closely associated with differentiation, tumor size, and lymph node metastasis. Moreover, the overexpression of circMET has been shown to promote the proliferation, metastasis, and immune evasion of NSCLC cells. Furthermore, NSCLC patients exhibit poor overall survival (OS) and progression-free survival (PFS) after surgery. circMET can be used as a promising novel prognostic biomarker for NSCLC.\(^\text{95}\) In addition, the expression of circSATB2 is upregulated in NSCLC tissues and cell lines compared with healthy controls. Further analysis showed that circSATB2 promotes the proliferation, migration, and invasion of NSCLC cells and is closely associated with metastasis in NSCLC. Clinically, circSATB2 is highly expressed in serum exosomes from NSCLC patients with a high sensitivity and specificity for clinical detection, indicating its great potential as a new diagnostic biomarker for NSCLC.\(^\text{11}\) Moreover, hsa_circ_0102533 has proven to be upregulated in NSCLC tissues and in whole blood. The knockdown of hsa_circ_0102533 significantly suppresses proliferation and induces apoptosis in NSCLC cells. Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) value of hsa_circ_0102533 is 0.774 in stage I–II NSCLC patients and 0.728 in stage III–IV NSCLC patients. hsa_circ_0102533 may become a promising early diagnostic biomarker of NSCLC.\(^\text{181}\)

In addition, Xian’s group found that exosomal circ_0047921, circ_0056285, and circ_0007761 have significant diagnostic value

| circRNA       | Expression | Function                        | Clinical relevance                                                                 | Reference          |
|---------------|------------|---------------------------------|------------------------------------------------------------------------------------|--------------------|
| hsa_circ_0002130 | up         | diagnostic biomarker            | hsa_circ_0002130 is highly expressed in serum exosomes from osimertinib-resistant NSCLC patients and shows diagnostic value for NSCLC patients; AUC = 0.792, 95% CI 0.676–0.909 (p < 0.005) | Ma et al.\(^\text{135}\) |
| hsa_circ_0046264 | up         | diagnostic and prognostic biomarker | high expression of hsa_circ_0046264 shows diagnostic and prognostic value for NSCLC patients; AUC = 0.971, sensitivity 95.1%, and specificity 97.3% in the tumor tissues; AUC = 0.915, sensitivity 92.7%, and specificity 95.7% in the serum of the patients; expression of hsa_circ_0046264 is associated with TNM stage (p = 0.015), age (p = 0.03), tumor size (p = 0.017), lymph node metastasis (p = 0.004), and OS (p < 0.05) | Liu et al.\(^\text{166}\) |
| hsa_circ_0007385 | up         | prognostic biomarker            | high expression of hsa_circ_0007385 shows diagnostic and prognostic value for NSCLC patients; AUC = 0.922, 95% CI 0.890–0.953, and OS (p = 0.008); high expression of hsa_circ_0007385 is associated with lymph node metastasis (p = 0.007), TNM stage (p = 0.004), and DFS (p = 0.028) | Lin et al.\(^\text{167}\) |
for NSCLC in the Chinese population. In their study, the expression levels of circ_0047921 and circ_0056285 were downregulated, whereas circ_0007761 was upregulated in NSCLC cases compared with controls. Correspondingly, the expression of circ_0047921, circ_0056285, and circ_0007761 distinguishes NSCLC patients from healthy controls with AUCs of 0.737, 0.625, and 0.750, respectively. Surprisingly, the panel of the three circRNAs showed AUC values of 0.926. Moreover, circRNA_100876 has been shown to be significantly upregulated in NSCLC tissues compared with their adjacent non-tumorous tissues, and its high expression is associated with lymph node metastasis and tumor staging. In addition, the NSCLC patients with high circRNA_100876 expression showed significantly shorter OS time compared with patients with low circRNA_100876 expression, indicating that circRNA_100876 might be a promising prognostic biomarker and therapeutic target for NSCLC. Moreover, the expression of circ_0001649 is closely correlated with some pathological features of NSCLC, including TNM stage, positive lymph node metastasis, and unfavorable prognosis. The overexpression of circ_0001649 significantly suppresses the growth and metastasis of NSCLC both in vitro and in vivo. circ_0001649 can be regarded as a new prognostic biomarker and potential therapeutic target of NSCLC.

In a recent study by Fu et al., they showed that hsa_circRNA_012515 is increased in NSCLC tissues, NSCLC cells, and gefitinib-resistant cells. Clinically, NSCLC patients with a high expression of hsa_circRNA_012515 show lower OS and shorter PFS compared with patients with a low expression of hsa_circRNA_012515. Moreover, hsa_circRNA_012515 expression is closely associated with the prognosis of NSCLC patients. hsa_circRNA_012515 shows great potential to be a diagnostic and prognostic biomarker for NSCLC. In addition, Peng et al. revealed that F-circEA produced from the EML4-ALK fusion gene specifically exists in the plasma of NSCLC patients with the EML4-ALK translocation. The overexpression of F-circEA contributes to NSCLC progression by promoting cell migration and invasiveness. The data from Peng’s study suggest that F-circEA possesses great diagnostic value as a “liquid biopsy” biomarker for EML4-ALK-positive NSCLC patients and guides EML4-ALK-targeted NSCLC therapy. These basic studies strongly suggest that circRNAs possess great potential to serve as promising biomarkers for the diagnosis and prognosis of NSCLC. However, the translational process from basic research to clinical application is very long, and more studies are required to overcome the limitations of circRNAs in clinics.

Therapeutic potential of circRNAs in NSCLC
A growing amount of evidence has highlighted the oncogenic or anti-tumoral function of circRNAs in NSCLC progression, suggesting their great potential as effective therapeutic targets or therapeutic vectors for NSCLC treatment. In addition, circRNAs have longer length and better stability than miRNAs, which provides a greater possibility for designing and screening drugs targeted at circRNAs. The techniques of gene silencing or overexpression targeting circRNAs may provide us with new insights into the development of NSCLC therapeutic strategies. For oncogenic circRNAs, RNAi targeting the back-splicing process can knock out specific circRNAs and avoid interference in their homologous linear mRNA expression. For instance, the high expression of hsa_circ_0062389 is reported to be positively associated with advanced TNM stage and lymph node metastasis. The silencing of hsa_circ_0062389 by siRNA has been shown to decrease the proliferation of NSCLC cells and cause cell-cycle arrest in the G0/G1 phase. Moreover, the CRISPR-Cas9 genome-editing technique is also an effective tool to treat NSCLC, as it can knock out specific genes with low off-target impacts. Li et al. found that circRNAs FECR1, -2, -3, -4, -5, and -6 are generated from the region of the FLI1 gene that the Cas9 guide RNAs (gRNAs) target. The knockout of FLI1 by the CRISPR-Cas9 system downregulates the expression of these circRNAs in NSCLC cells. In addition, screening or synthesizing new chemical drugs targeting circRNAs may provide new insights into NSCLC treatment. For anti-tumoral circRNAs, the exogenous introduction of circRNAs may serve as a therapeutic vector to play a role in the regulation of NSCLC progression. For instance, the overexpression of circNDUFB2 suppresses the growth and metastasis of NSCLC cells by enhancing the interaction of TRIM25 with IGF2BPs to promote IGF2BP degradation, indicating the potential therapeutic role of circNDUFB2 by blocking NSCLC progression. In addition, synthetic circRNAs containing miRNA binding sites may represent a simple, fast, and effective strategy for treating NSCLC. To summarize, using circRNAs as novel targets or drugs broadens our insight into NSCLC therapeutic strategies. However, challenges that limit their clinical application still exist, such as safety, off-target effects, and modes of targeted delivery, and further studies are required to resolve these issues.

CONCLUSION AND PERSPECTIVE
NSCLC is the most common malignant tumor type in the respiratory system, with high morbidity and mortality. Its pathogenesis is very complex and still unclear. Understanding the regulation mechanism of NSCLC progression may provide us with new insights into the development of NSCLC therapeutic strategies. circRNAs are recognized as crucial regulators in a variety of physiological and pathological processes due to their multiple functions, including miRNA sponging, protein interaction, gene expression regulation, and protein coding. With the rapid development of high-throughput sequencing techniques, a growing number of circRNAs have been found to be aberrantly expressed in NSCLC tissues. Most of them facilitate NSCLC progression, with only a few circRNAs exhibiting an anti-tumoral role, such as circ_0078767 and hsa_circ_0014130. circRNAs participate in the regulation of NSCLC progression by regulating the network of tumor gene expression and/or targeting key signaling pathways.

Early diagnosis and prognosis evaluation are important directions for the effective treatment of NSCLC. Therefore, identifying novel diagnostic and prognostic biomarkers, as well as therapeutic targets, will bring great benefits to the precise treatment of NSCLC patients. Due to the crucial role of circRNAs in NSCLC
progression, they are considered to be valuable diagnostic and prognostic biomarkers for NSCLC. In addition, circRNAs also exhibit great therapeutic potential for NSCLC patients. In recent years, therapeutic strategies based on circRNAs, such as RNAi, CRISPR-Cas9, and synthetic circRNAs, have been developed. However, circRNA research is in its infancy, and some challenges that limited the clinical application of circRNAs in NSCLC treatment still exist, such as safety, off-target effects, and modes of targeted delivery. Future studies should focus on elucidation of the exact mechanism of circRNAs in the regulation of NSCLC progression using large-scale clinical trials.

In conclusion, recent studies have demonstrated that circRNAs possess great potential to be valuable diagnostic and prognostic biomarkers, as well as therapeutic targets, in NSCLC treatment. However, the translational process from basic research to clinical application is very long. We believe that, through the continuous efforts of researchers, circRNAs will become a powerful tool that can be widely used in a variety of aspects of NSCLC treatment.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (81802822), the Natural Science Foundation of Shandong Province (ZR2018BH017 and ZR2021MC189), the China Postdoctoral Science Foundation (2018M642607), and the Qingdao Applied Basic Research Project (19-6-2-50-cg).

AUTHOR CONTRIBUTIONS
Y.L., X.A., W.Y., and Y.Z. collected the related papers. Y.L. drafted and wrote the manuscript. Y.L., X.A., and J.W. revised the manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424.
2. Hu, W., Bi, Z.Y., Chen, Z.L., Liu, C., Li, L.L., Zhang, F., Zhou, Q., Zhu, W., Song, Y.Y., Zhan, B.T., et al. (2018). Emerging landscape of circular RNAs in lung cancer. Cancer Lett. 427, 18–27.
3. Li, C., Zhang, L., Meng, G., Wang, Q., Lv, X., Zhang, I., and Li, J. (2019). Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 145, 2875–2889.
4. De Frapont, F., Gazzieri, S., Cho, W.C., and Eymin, B. (2019). Circular RNAs and RNA splice variants as biomarkers for diagnosis and therapeutic response in the liquid biopsies of lung cancer patients. Front Genet. 10, 390.
5. Xiao, M.S., Ay, Y., and Wilusz, J.E. (2020). Biogenesis and functions of circular RNAs come into focus. Trends Cell Biol. 30, 226–240.
6. Shan, C., Zhang, Y., Hao, X., Gao, J., Chen, X., and Wang, K. (2019). Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol. Cancer 18, 136.
7. Sanger, H.L., Klotz, G., Riesner, D., Gross, H.J., and Kleinschmidt, A.K. (1976). Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl. Acad. Sci. U S A 73, 3852–3856.
8. Chen, L.L. (2020). The expanding regulatory mechanisms and cellular functions of circular RNAs. Nat. Rev. Mol. Cell Biol. 21, 475–490.
9. Gao, Y.Z., Sun, J.Y., Chen, Y.X., Wen, C.C., and Wei, L. (2021). The roles of circRNAs in cancers: perspectives from molecular functions. Gene 767, 145182.
10. Li, S., Zhao, Y., and Chen, X. (2021). Microarray expression profile analysis of circular RNAs and their potential regulatory role in bladder carcinoma. Oncol. Rep. 45, 239–253.
11. Zhang, N., Nan, A., Chen, L., Li, X., Jia, Y., Qiu, M., Dai, X., Zhou, H., Zhu, J., Zhang, H., et al. (2020). Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells. Mol. Cancer 19, 101.
12. Lei, M., Zheng, G., Ning, Q., Zheng, J., and Dong, D. (2020). Translation and functional roles of circular RNAs in human cancer. Mol. Cancer 19, 30.
13. Li, J., Sun, D., Pu, W., Wang, J., and Peng, Y. (2020). Circular RNAs in cancer: biogenesis, function, and clinical significance. Trends Cancer 6, 319–336.
14. Li, M., Ding, W., Sun, T., Tarig, M.A., Xu, T., Li, P., and Wang, J. (2018). Biogenesis of circular RNAs and their roles in cardiovascular development and pathology. FEBS J. 285, 220–232.
15. Ma, Y., Zhang, X., Wang, Y.Z., Tian, H., and Xu, S. (2019). Research progress of circular RNAs in lung cancer. Cancer Biol. Ther. 20, 123–129.
16. Aufero, S., Reckman, Y.J., Pinto, Y.M., and Creemers, E.E. (2019). Circular RNAs open a new chapter in cardiovascular biology. Nat. Rev. Cardiol. 16, 503–514.
17. Han, B., Zhao, J., and Yao, H. (2018). Circular RNA and its mechanisms in disease: from the bench to the clinic. Pharmacol. Ther. 187, 31–44.
18. Jeck, W.R., Sorrentino, J.A., Wang, K., Slevin, M.K., Burd, C.E., Liu, J., Marzluff, W.F., and Sharpless, N.E. (2013). Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 19, 141–157.
19. Guo, J.U., Agarwal, V., Guo, H., and Bartel, D.P. (2014). Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 15, 409.
20. Abo:Haidar, M.G., Venkataraman, S., Gohhaini, A., Liu, B., and Ahmad, T. (2014). Novel coding, translation, and gene expression of a replicating covalently closed circular RNA of 220 nt. Proc. Natl. Acad. Sci. U S A 111, 14542–14547.
21. Qian, L., Yu, S., Chen, Z., Meng, Z., Huang, S., and Wang, P. (2018). The emerging role of circRNAs and their clinical significance in human cancers. Biochim. Biophys. Acta Rev. Cancer 1870, 247–260.
22. Li, X., Yang, L., and Chen, L.L. (2018). The biogenesis, functions, and challenges of circular RNAs. Mol. Cell 71, 428–442.
23. Bachmair-Heyda, A., Auer, K., Leitner, A.T., Auer, K., Klotz, G., Riesner, D., Gross, H.J., and Kleinschmidt, A.K. (2014). circRNA biogenesis and characterization of mammalian circular RNAs. Nat. Biotechnol. 32, 453–461.
24. Wang, L., Zhang, L., Fan, K., Cheng, Z.X., Sun, Q.C., and Wang, J.J. (2016). Circular RNA-ITCH suppresses lung cancer proliferation via inhibiting the Wnt/beta-catenin pathway. Biomed. Res. Int. 2016, 1579490.
25. Zhang, C., Ma, L., Niu, Y., Wang, Z., Xu, X., Li, Y., and Yu, Y. (2020). Circular RNA in lung cancer research: biogenesis, functions, and roles. Int. J. Biol. Sci. 16, 803–814.
26. Zhang, X.O., Wang, H.B., Zhang, Y., Lu, X., Chen, L.L., and Yang, L. (2014). Complementary sequence-mediated exon circularization. Cell 159, 134–147.
27. Ashwal-Fluss, R., Meyer, M., Pambudurai, N.R., Ivanov, A., Bartok, O., Hanan, M., Evantal, N., Memczak, S., Rajewsky, N., and Kadener, S. (2014). circular RNA biogenesis competes with pre-mRNA splicing. Mol. Cell 56, 55–66.
32. Conn, S.J., Pillman, K.A., Toubia, J., Conn, V.M., Salamanidou, M., Phillips, C.A., Roslan, S., Schreiber, A.W., Gregory, P.A., and Goodall, G.J. (2015). The RNA binding protein quaking regulates formation of circRNAs. Cell 160, 1125–1134.

33. Ivanov, A., Memczak, S., Wyler, E., Torti, F., Porath, H.T., Orejuela, M.R., Pechtucha, M., Levanon, E.Y., Landthaler, M., Dieterich, C., et al. (2015). Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 10, 170–177.

34. Fei, T., Chen, Y., Xiao, T., Li, W., Cato, L., Zhang, P., Cotter, M.B., Bowden, M., Liu, R.T., Zhao, S.G., et al. (2017). Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. Proc. Natl. Acad. Sci. U S A 114, E5207–E5215.

35. Wang, Y.F., Ao, X., Liu, Y., Ding, D., Jiao, W.J., Yu, Z., Zhai, W.X., Deng, S.H., He, Y.Q., Guo, H., et al. (2019). MicroRNA-608 promotes apoptosis in non-small lung cancer cells treated with doxorubicin through the inhibition of TPA4. Front. Genet. 10, 809.

36. Biermann, J., Picollo, M.T., Viererk, J., and Thum, T. (2016). Non-coding RNAs in development and disease: background, mechanisms, and therapeutic approaches. Physiol. Rev. 96, 1297–1325.

37. Ghaifouri-Fard, S., Abak, A., Shoorei, H., Mohaqeni, M., Majdipoor, J., Sayad, A., and Taberti, M. (2021). Regulatory role of microRNAs on PTEN signaling. Biomed. Pharmacother. 133, 110986.

38. Fan, X., Weng, X., Zhao, Y., Chen, W., Gan, T., and Xu, D. (2017). Circular RNAs in cardiovascular disease: an overview. Biomed. Res. Int. 2017, 5135781.

39. Chen, C.Y., and Sarnow, P. (1995). Initiation of protein synthesis by the eukaryotic translational apparatus on circular RNAs. RNA 1, 95–110.

40. Conn, S.J., Pillman, K.A., Toubia, J., Conn, V.M., Salamanidou, M., Phillips, C.A., Roslan, S., Schreiber, A.W., Gregory, P.A., and Goodall, G.J. (2015). The RNA binding protein quaking regulates formation of circRNAs. Cell 160, 1125–1134.

41. Legnini, I., Di Timoteo, G., Rossi, F., Morlando, M., Briganti, F., Stendardi, O., Fatica, A., Santini, T., Andronache, A., Wade, M., et al. (2017). Circ-ZNF609 is a circular RNA that can be translated and functions in myogenesis. Mol. Cell 66, 22–37 e29.

42. Zhang, Y., Fan, X., Mao, M., Song, X., Wu, P., Zhang, Y., Jin, Y., Yang, Y., Chen, L.L., Wang, Y., et al. (2017). Extensive translation of circular RNAs driven by N6-methyladenosine. Cell 27, 626–641.

43. Zitnay, G., Papavasileiou, P., and Rajeswky, N. (2014). circBase: a database for circular RNAs. RNA 20, 1666–1670.

44. Gislason, S., Dau, S., Sen, R., Basak, P., and Chakraborti, J. (2013). circRNA2Traits: a comprehensive database for circular RNA potentially associated with disease and traits. Front Genet. 4, 283.

45. Liu, Y.C., Li, J.R., Sun, C.H., Andrews, E., Chao, R.F., Lin, F.M., Weng, S.L., Hsu, S.D., Huang, C.C., Cheng, C., et al. (2016). CircNet: a database of circular RNAs derived from transcriptome sequencing data. Nucleic Acids Res. 44, D209–D215.

46. Xue, F., Liu, S., Wang, J., Xuan, J., Zhang, K., Qu, L., Zheng, L., and Yang, J. (2021). DeepBase v3.0: expression atlas and interactive analysis of ncRNAs from thousands of deep-sequencing data. Nucleic Acids Res. 49, D877–D883.

47. Dudekula, D.B., Panda, A.C., Grammatikakis, I. D., S., Abdelmohsen, K., and Gorospe, M. (2016). CircInteractome: a web tool for exploring circular RNAs and their interacting proteins and microRNAs. RNA Biol. 13, 34–42.

48. Xie, S., Feng, J., Chen, K., Ma, Y., Gong, J., Cai, F., Jin, Y., Gao, Y., Xia, L., Chang, H., et al. (2018). CICbase: a database for cancer-specific circular RNAs. Nucleic Acids Res. 46, D925–D929.
71. Dong, R., Ma, X.K., Li, G.W., and Yang, L. (2018). CIRCPedia v2: an updated data-
base for comprehensive circular RNA annotation and expression comparison. 
Genomics Proteomics Bioinformatics 16, 226–233.

72. Chen, X., Han, P., Zhou, T., Guo, X., Song, X., and Li, Y. (2016). circRNAdb: a 
comprehensive database for human circular RNAs with protein-coding annotations. 
Sci. Rep. 6, 34985.

73. Wu, S.M., Liu, H., Huang, P.J., Chang, I.Y., Lee, C.C., Yang, C.Y., Tsai, W.S., and 
Tan, B.C. (2018). circRNAANet: an integrated web-based resource for mapping 
functional networks of long or circular forms of noncoding RNAs. Gigascale 7, 
1–10.

74. Zhao, Z., Wang, K., Wu, F., Wang, W., Zhang, K., Hu, H., Liu, Y., and Jiang, T. 
(2018). circRNA disease: a manually curated database of experimentally supported 
circRNA-disease associations. Cell Death Dis. 9, 475.

75. Li, J.H., Liu, S., Zhou, H., Qu, L.H., and Yang, J.H. (2014). starBase v2.0: decoding 
miRNA-ceRNA, miRNA-nncRNA and protein-RNA interaction networks from 
large-scale CLIP-Seq data. Nucleic Acids Res. 42, D92–D97.

76. Zhang, X.O., Dong, R., Zhang, Y., Zhang, J.L., Luo, Z., Zhang, J., Chen, L.L., and 
Yang, L. (2016). Diverse alternative back-splicing and alternative splicing landscape of 
circular RNA. Genome Res. 26, 1277–1287.

77. Li, S., Li, Y., Chen, B., Zhao, J., Yu, S., Tang, Y., Zheng, Q., Li, Y., Wang, P., He, X., 
et al. (2018). exoRBase: a database of circRNA, IncRNA and miRNA in human blood 
exosomes. Nucleic Acids Res. 46, D106–D112.

78. Yang, Z., Li, X., Zhao, J., Qian, F., Feng, C., Li, Y., Zhang, J., Jiang, Y., Yang, W., 
et al. (2019). TRCirc: a resource for transcriptional regulation information of 
circRNAs. Brief Bioinform 20, 2327–2333.

79. Wei, S., Zheng, Y., Jiang, Y., Li, X., Geng, J., Shen, Y., Li, Q., Wang, X., Zhao, C., 
et al. (2019). The circRNA circPTFRA suppresses epithelial-mesenchymal 
transitioning and metastasis of NSCLC cells by sponging miR-96-5p. Ebiomedicine 44, 
182–193.

80. Zhang, Z.Y., Gao, X.H., Ma, M.Y., Zhao, C.L., Zhang, Y.L., and Guo, S.S. (2020). 
circRNA_101237 promotes NSCLC progression via the miRNA-490-3p/MAPK1 
axis. Sci. Rep. 10, 9024.

81. Wang, L., Tong, X., Zhou, Z., Wang, S., Lei, Z., Zhang, T., Liu, Z., Zeng, Y., Li, C., 
Zhan, J., et al. (2018). Circular RNA hsa_circ_008035 (circPTK2) inhibits TGF-
beta-induced epithelial-mesenchymal transition and metastasis of NSCLC cells by 
sponging miR-195-5p. Cancer Manag. Res. 10, 289–301.

82. Yang, J., Jia, Y., Wang, B., Yang, S., Du, K., Luo, Y., Li, Y., and Zhu, B. (2020). 
Circular RNA TUBA1C accelerates the progression of non-small cell lung cancer 
by sponging miR-143-3p. Cell Signal. 74, 106969.

83. Hong, W., Zhang, Y., Ding, J., Yang, Q., Xie, H., and Gao, X. (2020). circHIPK3 acts 
as competing endogenous RNA and promotes non-small cell lung cancer progres-
sion through the miR-107/BDNF signaling pathway. Biomed. Res. Int. 2020, 
6075902.

84. Yu, C., Ying, J., Yu, K., Shen, W., and Jiang, M. (2020). CircRNA_074027 contributes 
to nonsmall cell lung cancer progression by upregulating CUL4B expression through 
miR-335-5p. Cancer Biother. Radiopharm. https://doi.org/10.1089/cbr.2020.3579.

85. Cheng, F., Yu, J., Zhang, X., Dai, Z., and Fang, A. (2020). CircSEC31A promotes 
the malignant progression of non-small cell lung cancer through regulating SEC31A 
expression via sponging miR-376a. Cancer Manag. Res. 12, 11527–11539.

86. Li, G., Zhao, C., Zhang, H., Yu, J., Sun, Y., and Zhang, Y. (2020). Hsa_circ_0046263 
drives the carcinogenesis and metastasis of non-small cell lung cancer through the 
promotion of NOVA2 by absorbing miR-940 as a molecular sponge. Cancer Manag. 
Res. 12, 12779–12790.

87. Ma, D., Qin, Y., Huang, C., Chen, Y., Han, Z., Zhou, X., and Liu, H. (2020). Circular 
RNA ABCB10 promotes nonsmall cell lung cancer progression by increasing E2F5 
expression through sponging miR-584-5p. Cell Cycle 19, 1611–1620.

88. Cao, X., Li, F., Shao, J., Lv, J., Zhang, A., Dong, W., and Zhu, F. (2020). Circular RNA 
hsa_circ_0102231 sponges miR-145 to promote nonsmall cell lung cancer cell 
proliferation by up-regulating the expression of RBBP4. J. Biochem. 169, 65–73.

89. Wei, H., Li, L., Zhang, H., Xu, F., Chen, L., Che, G., and Wang, Y. (2021). Circ-
FOXM1 knockdown suppresses nonsmall cell lung cancer development by regu-
lating the miR-149-5p/ATG5 axis. Cell Cycle 20, 166–178.

90. Ma, Q., Huai, B., Liu, Y., Jia, Z., and Zhao, Q. (2021). Circular RNA circ_0020123 
promotes nonsmall cell lung cancer progression through miR-384/TRIM44 Axis. 
Cancer Manag. Res. 13, 75–87.

91. Hong, W., Xue, M., Jiang, J., Zhang, Y., and Gao, X. (2020). Circular RNA circ-
CPA4/let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and 
immune evasion in non-small cell lung cancer (NSCLC). J. Exp. Clin. Cancer 
Res. 39, 149.

92. Zhang, S., Zeng, X., Ding, T., Guo, L., Li, Y., Ou, S., and Yuan, H. (2018). Microarray 
profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA 
biomarker in nonsmall cell lung cancer. Sci. Rep. 8, 2878.

93. Zhao, J., Li, L., Wang, Q., Han, H., Zhan, Q., and Xu, M. (2017). CircRNA expression 
profile in early-stage lung adenocarcinoma patients. Cell Physiol. Biochem. 44, 
2138–2146.

94. Wang, C., Tan, S., Liu, W.R., Lei, Q., Qiao, W., Wu, Y., Liu, X., Cheng, W., Wei, Y.Q., 
Peng, Y., et al. (2019). RNA-Seq profiling of circular RNA in human lung adenocar-
cinoma and squamous cell carcinoma. Mol. Cancer 18, 134.

95. Liu, Y.T., Han, X.H., Xing, P.Y., Hu, X.S., Hao, X.Z., Wang, Y., Li, J.L., Zhang, Z.S., 
Yang, Z.H., and Shi, Y.K. (2019). Circular RNA profiling identified as a biomarker 
for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer. 
J. Thorac. Dis. 11, 1779–1787.

96. Li, L., Sun, D., Li, X., Yang, B., and Zhang, W. (2021). Identification of key circRNAs 
in nonsmall cell lung cancer. Am. J. Med. Sci. 361, 98–105.
109. Li, X.Y., Liu, Y.R., Zhou, J.H., Li, W., Guo, H.H., and Ma, H.P. (2019). Enhanced expression of circular RNA hsa_circ_0009848 promotes cells proliferation and metastasis in non-small cell lung cancer by modulating Wnt/beta-catenin pathway. Eur. Rev. Med. Pharmacol. Sci. 23, 3366–3374.

110. Zhao, M., Ma, W., and Ma, C. (2020). Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/beta-catenin pathway. Biomed. Pharmacother. 129, 110461.

111. Gao, F., Jia, L., Han, J., Wang, Y., Luo, W., and Zeng, Y. (2020). Circ-ZNF124 down-regulation inhibits non-small cell lung cancer progression partly by inactivating the Wnt/beta-catenin signaling pathway via modulating the miR-496/YES1 axis. Anticancer Drugs 32, 257–268.

112. Ding, L., Yao, W., Lu, J., Gong, J., and Zhang, X. (2018). Upregulation of circ_001569 predicts poor prognosis and promotes cell proliferation in non-small cell lung cancer by regulating the Wnt/beta-catenin pathway. Oncol. Lett. 16, 453–458.

113. Tian, F., Yu, C.T., Ye, W.D., and Wang, Q. (2017). Cinnamaldehyde induces cell apoptosis mediated by a novel circular RNA hsa_circ_0043256 in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 493, 1260–1266.

114. Bai, L., Peng, X., and Sun, R. (2020). Knockdown of circPRKCA Restrained cell activation of the PI3K/AKT apoptosis-inhibiting pathway. Thorac. Cancer 11, 268–272.

115. Huang, M.S., Liu, J.Y., Xia, X.B., Liu, Y.Z., Li, X., Yin, J.Y., Peng, J.B., Wu, L., Zhang, R.S., Garces, Y.I., Yang, P., et al. (2014). Wnt signaling pathway pharmacogenetics in predicting poor prognosis and promotes cell proliferation in non-small cell lung cancer. Biochem. Biophys. Res. Commun. 453, 475–480.

116. Liu, Y., Ao, X., Ding, W., Zhang, Y., Ding, D., and Liu, Y. (2020). TCF21: a critical transcription factor in health and cancer. J. Mol. Med. (Berl) 98, 1055–1068.

117. Liu, Y., Ding, W., Ge, H., Pronusamy, M., Wang, Q., Han, X., Wu, W., Zhang, Y., Yu, W., Ao, X., et al. (2019). FOXK transcription factors: regulation and critical role in cancer. Cancer Lett. 458, 1–12.

118. Zheng, J.P., Dai, Y.M., Chen, Z., Chen, Q., Zheng, Y., Lin, X., and Cui, T.J. (2020). Circular RNA circ-ARCB10 promotes non-small cell lung cancer proliferation and inhibits cell apoptosis through repressing KISS1. Eur. Rev. Med. Pharmacol. Sci. 24, 7200.

119. Lv, Y.S., Wang, C., Li, L.X., Han, S., and Li, Y. (2020). Effects of circular RNA_103993 on the proliferation and apoptosis of NSCLC cells through miR-1271/ERK signaling pathway. Eur. Rev. Med. Pharmacol. Sci. 24, 8384–8393.

120. Wang, M., Shi, J., Jiang, H., Xu, K., and Huang, Z. (2020). Circ_0014130 participates in the proliferation and apoptosis of non-small cell lung cancer cells via the miR-142-5p/IGF-1 Axis. Cancer Biother. Radiopharm. 35, 233–240.

121. Ren, T., Liu, C., Hou, J., and Shan, F. (2020). Hsa_circ_0043265 suppresses proliferation, metastasis, EMT and promotes apoptosis in non-small cell lung cancer through miR-25-3p/FOXO2 pathway. Onco Targets Ther. 13, 3867–3880.

122. Yang, Z., Xu, X., and Song, C. (2020). Circular RNA Lα-related protein 4 inhibits nonsmall cell lung cancer cell proliferation while promotes apoptosis through sponging microRNA-21-5p. Cancer Biother. Radiopharm. https://doi.org/10.1089/cbr.2020.3707.

123. Chen, L., Nan, A., Zhang, N., Jia, Y., Li, X., Ling, Y., Dai, J., Zhang, S., Yang, Q., Yi, et al. (2019). Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol. Cancer 18, 13.

124. Chi, Y., Luo, Q., Song, Y., Yang, F., Wang, Y., Jin, M., and Zhang, D. (2019). Circular RNA circPIPS1A promotes non-small cell lung cancer proliferation and metastasis through miR-600/IFIT1-alpha regulation. J. Cell Biochem. 120, 19019–19030.

125. Liu, Y., Ao, X., Zou, J., Liu, Y., Ao, X., Wu, H., Huang, C., Wei, Q.Y., and Peng, Y. (2019). Circular RNA f-circEA-2a derived from EML4-ALK fusion gene promotes cell migration and invasion in non-small cell lung cancer. Mol. Cancer 17, 138.

126. Wu, K., Liao, Y., Geng, Y., He, J., Zhou, J.K., Tan, S., Pu, W., Huang, C., Wei, Q.Y., and Peng, Y. (2019). Circular RNA f-circSR derived from SLC34A2-ROS1 fusion gene promotes cell migration in non-small cell lung cancer. Mol. Cancer 18, 98.

127. Xue, Y.B., Ding, M.Q., Xue, L., and Luo, J.H. (2019). CircAGFG1 sponges miR-203 to promote EMT and metastasis of non-small-cell lung cancer by upregulating ZNF281 expression. Thorac. Cancer 10, 1692–1701.

128. Liu, Y., Ao, X., Zou, J., Jin, X., Xu, Z., Hu, G., Jiang, X., Chen, M., and Wu, H. (2015). FOX2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BRD1. Sci. Rep. 5, 8796.

129. Cui, D., Qian, R., and Li, Y. (2020). Circular RNA circ-CMPK1 contributes to cell proliferation of non-small cell lung cancer by elevating cyclin D1 via sponging miR-302e. Mol. Genet. Genomic Med. 8, 4999.

130. Lu, H., Xie, X., Wang, K., Chen, Q., Cai, S., Liu, D., Luo, J., and Kong, J. (2020). Circular RNA hsa_circ_006157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells. Mol. Cell Biochem. 475, 63–77.

131. Chen, T., Yang, Z., Liu, C., Wang, L., Yang, J., Chen, L., and Li, W. (2019). Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p. Cell Prolif. 52, e12548.

132. Li, H., Liu, F., and Qin, W. (2020). Circ_0072083 knockdown suppresses non-small cell lung cancer cell proliferation and metastasis via miR-204-5p/FOXO3a axis: a potential therapeutic strategy for oral squamous cell carcinoma. EBioMedicine 49, 6–8.
187. Lin, Y., Su, W., and Lan, G. (2020). Value of circular RNA 0007385 in disease monitoring and prognosis estimation in non-small-cell lung cancer patients. J. Clin. Lab. Anal. 34, e23338.

188. Tan, S., Gou, Q., Pu, W., Guo, C., Yang, Y., Wu, K., Liu, Y., Liu, L., Wei, Y.Q., and Peng, Y. (2018). Circular RNA F-circEA produced from EML4-ALK fusion gene as a novel liquid biopsy biomarker for non-small cell lung cancer. Cell Res. 28, 693–695.

189. Boutros, M., and Ahringer, J. (2008). The art and design of genetic screens: RNA interference. Nat. Rev. Genet. 9, 554–566.

190. Jiang, C., Lin, X., and Zhao, Z. (2019). Applications of CRISPR/Cas9 technology in the treatment of lung cancer. Trends Mol. Med. 25, 1039–1049.

191. Li, L., Li, W., Chen, N., Zhao, H., Xu, G., Zhao, Y., Pan, X., Zhang, X., Zhou, L., Yu, D., et al. (2019). FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer. Clin. Cancer Res. 25, 1302–1317.